Conversely, treatment with immune stimulants such as checkpoint inhibitors, IL-7, IFN-γ, and GM-CSF, currently either proposed or in active clinical trials in COVID-19 (15, 33), could exacerbate a dysfunctional and robust inflammatory response and worsen organ injury. The gene discussed is IL7; the disease is COVID-19.